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Abstract
Background: Modified Lingguizhugan Decoction (MLD) came from famous Chinese medicine Linggui Zhugan
Decoction. The MLD is used for the treatment of metabolic syndrome in the clinical setting. Our study focuses on
the comprehensive treatment of MLD incorporated with dietary restriction and exercise in a rat model of the
metabolic syndrome (MS).
Methods: Rats were divided into five groups: control group (Cont), high-fat diet group (HFD), high-fat diet
incorporated with dietary restriction group (HFD-DR), exercise incorporated with dietary restriction group (HFD-DR-Ex)
and MLD incorporated with dietary restriction and exercise group (HFD-DR-Ex-MLD). Treatments were conducted
for 1 week after feeding high-fat diet for 12 weeks. The effects of treatments on high fat diet-induced obesity,
hyperglycemia, hyperlipidemia, hypertension, hepatic injury and insulin resistance in rats of MS were examined. In
addition, the tumor necrosis factor-α (TNF-α), leptin and protein kinase B (PKB) in rats serum and liver were also
examined by enzyme-linked immunosorbent assay (ELISA).
Results: After a week’s intervention by dietary restriction, dietary restriction incorporated with exercise or MLD,
compared with HFD rats, the relative weight of liver and fat, levels of triglyceride, total cholesterol, low-density
lipoprotein, free fatty acid, aspartate aminotransferase, glutamic-pyruvic transaminase and alkaline phosphatase,
insulin, were significantly decreased (p < 0.05 or 0.01). This treatment also inhibited abnormal increases of TNF-α,
leptin and PKB in serum and liver.
Conclusion: MLD incorporated with dietary restriction and exercise treatment exhibit effects in alleviating high-
fat diet-induced obesity, hyperglycemia, hyperlipidemia, hypertension, hepatic injury and insulin resistance, which
are possibly due to the down-regulation of TNF-α, leptin and PKB.
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Background
Metabolic syndrome (MS) is a chronic systemic disorder
disease characterized by abdominal obesity, abnormal
glucose metabolism, blood lipid disorders, high blood
pressure and cardiovascular disease [1, 2]. MS is a lead-
ing cause of mortality and morbidity in industrialized
countries [3]. In the United States, national surveys have
observed that the prevalence of MS was 23.7% in the
general population [4]. In China, a survey of 35–74 year-
old adults showed that the prevalence of MS was 10.0
and 23.3% for males and females, respectively [5].
MS is a disease composed of different risk factors such
as obesity, type 2 diabetes or dyslipidemia. The preva-
lence of this syndrome is increasing worldwide in paral-
lel with the rise in obesity and indicates that greater
attention should be paid to it [6]. Obesity is now a
worldwide pandemic and is expected to affect 10% of
the global population by 2030 if the current trend is
maintained [7]. Obesity results from an imbalance be-
tween caloric intake and energy expenditure, leading to
an excess of energy, which is stored as fat mainly in
white adipose tissue [8]. It is well recognized that in-
appropriate diet and inactivity are important determi-
nants of MS and other chronic disorders. Dietary
restriction and exercise have drawn attention in recent
years due to its effect on weight loss to reduce the risk
factors of cardiovascular disease in obese patients [9].
Clinical and experimental evidence showed that diet
restriction and exercise can be a very effective strat-
egy to prevent the development of a metabolic syn-
drome [10, 11].
Traditional Chinese medicine (TCM) has its unique
advantages in preventing these diseases. Linggui Zhugan
Decoction (LZD) was a famous Chinese medicine for-
mulae which was documented in Jin Gui Yao Lue, a clas-
sical work of Zhongjing Zhang written in the Han
dynasty. Zhang JJ et al. observed alternate-day fasting
therapy combined with LZD could reduce body weight,
total cholesterol (TC), triglyceride (TG) concentrations
and elevate glutathione in hyperlipidemic rats [12]. LZD
combined calorie restriction could reduce the body
weight, fasting plasma glucose, and insulin resistance
index of insulin resistance rats [13]. The Modified
Lingguizhugan Decoction (MLD) came from LZD and
showed better efficacy. MLD can lower body weight,
blood pressure (BP), blood glucose, the level of TC, TG
and low-density lipoprotein (LDL), elevate high-density
lipoprotein (HDL), regulate adiponectin, leptin, insulin
and insulin resistance index to a normal level in MS
model rats, which suggested that MLD has effects on
regulation fat and saccharide metabolism [14–16]. The
MLD incorporated with short-term diet restriction and
exercise is a new kind of natural therapy incorporating
Chinese medicine with fasting therapy systematically
[17]. The treatment requires the participants to have less
solid food, but drink millet soup. The MLD with the ef-
fects of warming and resolving the mucus, strengthening
the spleen and removing the turbidity is simultaneously
administered to restore normal function of the spleen in
transportation and transformation [18, 19]. Therefore,
this study investigated effects of dietary restriction, diet-
ary restriction incorporated with exercise, dietary restric-
tion incorporated with exercise and MLD on high-fat
diet-induced MS in rats.
Methods
Preparation of MLD
MLD was composed of Poria cocos (Schw.) Wolf, Cinna-
momum cassia Presl, Atractylodes lancea (Thunb.) DC.,
Glycyrrhiza uralensis Fisch., Codonopsis pilosula
(Franch.) Nannf. and Rheum palmatum L at the ratio of
12:9:6:6:9:9. Crude drugs are offered by Sanjiu Medical
and Pharmaceutical Incorporation (Shenzhen, China).
All of these herbal materials were the same batch during
the whole experimental process and were identified by
School of Chinese Materia Medica, Guangzhou Univer-
sity of Chinese Medicine. A voucher specimen of each
species was also deposited at Guangzhou University of
Chinese Medicine. To prepare the MLD, the mixture of
the six herbs were pulverized to coarse powder, refluxed
in water two times each for 1 h. The extracts were com-
bined and filtrated. The filtration were concentrated to
0.617 g/mL (crude drug content) and stored at 4 °C until
use. To ensure the quality and stability of the MLD, we
use high performance liquid chromatography (HPLC) to
assay important efficacy components in MLD (dehydro-
tumulosic acid, cinnamic acid and glycyrrhizic acid). The
concentrations of the three components were: dehydro-
tumulosic acid (75.87 μg/ml), cinnamic acid (78.36 μg/ml)
and glycyrrhizic acid (247.21 μg/ml). The chemical struc-
tures and chromatograms are shown in Fig. 1.
Animals
The study protocol was approved by the Institutional
Animal Care and Use Committee of Guangzhou University
of Chinese Medicine and in accordance with the principles
outlined in the NIH Guide for the Care and Use of Labora-
tory Animals. Fifty adult Sprague-Dawley male rats (SPF
grade) weighing 200 ± 20 g, 6- to 7-week-old, were kept in
a temperature and humidity controlled animal facility and
maintained on a 12 h light/dark cycle with access to food
and water ad libitum. Experiments were conducted during
the light phase. All rats had free access to diets and water
for 1 week prior to the experiments. The diet was a semi-
purified modified D12451 formulation with energy sources
containing 36% energy and 1% cholesterol. The diet com-
position was similar to a normal human diet.
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Animal treatment
After 1 week of acclimatization, 50 rats were randomly
divided into five groups with ten animals in each group.
(1) Control group (Cont) that accepted normal chow
(energy content: protein 23%, carbohydrate 67%, and fat
10%); (2) high-fat diet group (HFD) that fed with high-
fat diet (energy content: protein 12%, carbohydrate 18%,
and fat 70% including 8% from soya oil and 62% satu-
rated fat from lard) for 12 weeks to induce metabolic
syndrome model. This high-fat diet enriched in satu-
rated fat and incorporated with moderate-to-low carbo-
hydrate content has been previously used as an
obesogenic (causing high adiposity) and a diabetogenic
(inducing insulin resistance) food in rats [20]; (3) high-
fat diet incorporated with dietary restriction group
(HFD-DR) that fed with 30% of high-fat diet; (4) exercise
incorporated with dietary restriction group (HFD-DR-
Ex) adhered to swim for 45 min everyday on the basis of
HFD-DR; (5) MLD incorporated with dietary restriction
and exercise group (HFD-DR-Ex-MLD) that gave MLD
(correspond to 6.17 g crude drug/kg body weight) by
oral administration everyday on the basis of HFD-DR-
Ex. Treatments were conducted for 1 week after feeding
high-fat diet for 12 weeks.
After a week of treatments, all rats were anesthetized
with an intraperitoneal injection of chloralic hydras
(3.5 mg/kg). After sacrifice of the rats, blood samples
were collected from the abdominal aorta into tubes;
serum was separated by centrifugation at 3500 rpms for
10 min and was kept frozen at −80 °C until chemical as-
says. The epididymal and retroperitoneal fat pads were
excised and weighed. The liver was also excised and
weighed, then took a leaf of liver fixed with neutral
formaldehyde for histological study, the rest was kept
at −80 °C for ELISA.
Exercise training
The exercise training protocol was adapted from a previ-
ously published procedure [21]. Swimming was done in
a cylindrical tank, 180 cm in diameter and 50 cm in
height, temperature (29 ± 2) °C, according to the proto-
col. The animals were placed in the tank daily at the
same hour (11:00–11:45 A.M.), and the training was
monitored by the same person. The rats swam for a
week (45 min/day), after each exercise session, the
animals were dried and kept in a warm environment.
Other group rats were restricted to cage activity.
Blood pressure
Systolic blood pressure was measured using a tail-cuff
system (Shanghai Alcott Biotech Co., Ltd., China) before
and at the end of the experimental period. All of the
animals were placed in a restrainer for 15 min, a cuff
was attached to their tail, and the blood pressure was re-
corded. For both measures, the rats underwent an adap-
tation period of 7 days to familiarize them with the
procedure, which began right after the adaptation
Fig. 1 Chemical structures and HPLC analysis of major components in MLD. a dehydrotumulosic acid (C31H48O4, molecular weight: 484.71); b
glycyrrhizic acid (C42H62O16, molecular weight: 822.93); c cinnamic acid (C9H8O2, molecular weight: 148.16); d HPLC analysis of dehydrotumulosic
acid and glycyrrhizic acid in MLD; e HPLC analysis of cinnamic acid in MLD
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period. Valid blood pressure values were obtained as de-
scribed at the 8th day of measurements.
Body weight and relative weights of adipose tissue
and liver
After sacrifice rats, the epididymal and retroperitoneal
fat pads were excised and weighed. The liver was also
cleaned and the wet weights were measured. Weights
were calculated as percentage of wet weight to body
weight.
Biochemical determinations
Serum glucose was assayed by the fast blood glucose
meter. Serum TG, TC, HDL, LDL, free fatty acid (FFA),
aspartate aminotransferase (AST), glutamic-pyruvic
transaminase (ALT) and alkaline phosphatase (ALP)
were assayed using kits purchased from Nanjing
Jiancheng Bioengineering Institute (Nanjing, China).
Enzyme-linked immunosorbent assay (ELISA)
Serum was prepared from peripheral blood. Liver tissues
were removed, homogenated with ice-cold PBS, centri-
fuged at 12,000 rpms for 20 min and separated the
supernatant. The levels of insulin, leptin, protein kinase
B (PKB) and tumor necrosis factor-α (TNF-α) in serum
and liver tissue were measured by ELISA according to
the manufacture instructions and calculated according
to the standard curve.
Histological study
An equal liver sample from each rat were obtained and
fixed in 10% neutral formalin, dehydrated in ascending
grades of alcohol and cleared in benzol. Samples from
each group were embedded in paraffin with a melting
point between 55 and 56 °C for 4 h and then paraffin
blocks were prepared. Paraffin sections were made at
5 μm and stained with (1) hematoxylin and eosin (HE):
for normal histology and histopathology; (2) periodic
acid Schiff (PAS): to detect polysaccharides such as
glycogen and mucosubstances such as glycoproteins,
glycolipids and mucins in liver tissues. The Schiff
reagent gives a purple-magenta color, followed by
light microscopy for demons demonstrating any histo-
logical changes.
Statistical analysis
All values are expressed as mean ± standard error of
the mean (S.E.M.). Differences among groups were de-
termined by one-way ANOVA with Tukey’s post hoc
test. Statistical analyses were performed using SPSS
version 11.0 (SPSS Inc., Chicago, USA). Statistical
significance was confirmed when P values were less
than 0.05 or 0.01.
Fig. 2 Changes in each group (n = 10) on body weight (a) and relative weight of adipose (b) and liver (c). Compared with Control group rats,
##P < 0.01; compared with HFD rats, *P < 0.05, **P < 0.01, respectively
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Results
Body weight and relative weights of adipose tissue
and liver
Figure 2 shows the body weight and relative weights of
adipose tissue and liver after the intervention period.
Compared with Cont rats, body weight (Fig. 2a) and
relative weights of adipose tissue (Fig. 2b) and liver
(Fig. 2c) of HFD rats was significantly increased (P < 0.01);
compared with HFD rats, the body weight (Fig. 2a) and
relative weight of adipose tissue (Fig. 2b) and liver (Fig. 2c)
of HFD-DR-Ex and HFD-DR-Ex-MLD rats were signifi-
cantly lower than the HFD rats (P < 0.05 or 0.01).
Levels of TC, TG, LDL, HDL and FFA in serum
The serum levels of TC, TG, LDL, HDL and FFA are
demonstrated in Fig. 3. Compared with Cont rats, HFD
rats resulted in significant increase in TC, TG, LDL and
FFA and decrease in HDL (P < 0.01). Compared with
HFD rats, levels of TC were significantly lower in HFD-
DR-Ex-MLD rats (P < 0.01, Fig. 3a), levels of TG were
significantly lower in HFD-DR, HFD-DR-Ex and HFD-
DR-Ex-MLD rats (P < 0.05 or 0.01, Fig. 3b), levels of
LDL were significantly lower in HFD-DR-Ex and HFD-
DR-Ex-MLD rats (P < 0.05 or 0.01, Fig. 3c), levels of
HDL were higher in HFD-DR and HFD-DR-Ex-MLD
rats (P < 0.05 or 0.01, Fig. 3d), levels of FFA were signifi-
cantly lower in HFD-DR-Ex and HFD-DR-Ex-MLD rats
(P < 0.05 or 0.01, Fig. 3e).
Levels of AST, ALT and ALP in serum
The serum levels of AST, ALT and ALP are demon-
strated in Fig. 4. Compared with Cont rats, HFD rats
resulted in significant increase in ALT, AST and ALP
(P < 0.01). Compared with HFD rats, levels of AST
(Fig. 4a) were significantly lower in HFD-DR-Ex and
HFD-DR-Ex-MLD rats (P < 0.05 or 0.01), level of ALT
Fig. 3 Changes in each group (n = 10) on TC (a), TG (b), LDL (c), HDL (d) and FFA (e). Compared with Control group rats, ##P < 0.01; compared
with HFD rats, *P < 0.05, **P < 0.01, respectively
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(Fig. 4b) was significantly lower in HFD-DR-Ex-MLD
rats (P < 0.05), levels of ALP (Fig. 4c) were significantly
lower in HFD-DR, HFD-DR-Ex and HFD-DR-Ex-MLD
rats (P < 0.01).
Photomicrograph of rat’s liver
As HE stain of rat’s liver revealed, Cont rats (Fig. 5a)
histological architecture of liver showed normal lobular
structure with central vein, hepatocytes and hepatic
plates. Liver of HFD rats (Fig. 5b) showed serious peri-
portal fibrosis, vacuolated cytoplasm and cellular infiltra-
tion. Liver of HFD-DR rats (Fig. 5c) showed somewhat
normal liver cells and nuclei, compared to HFD group,
vacuolated cytoplasm decreased significantly. Liver of
HFD-DR-Ex rats (Fig. 5d) showed some cellular infiltra-
tions. Liver of HFD-DR-Ex-MLD rats (Fig. 5e) showed
small mean cell size, which was more or less similar to
the levels of the Cont rats. There was an obvious differ-
ence in cell size distribution in each group.
As PAS stain of rat’s liver revealed, Cont rats (Fig. 6a)
shows normal architecture and glycogen distribution in
the liver cell. Liver of HFD rats (Fig. 6b) showed changes
in all hepatocytes. These cells became large with vacuo-
lated cytoplasm and little red stained granules. Liver of
HFD-DR rats (Fig. 6c) showed less cell enlargement and
more red stained than HFD rats. Liver of HFD-DR-Ex
rats (Fig. 6d) showed less hepatocytes and small cells
with red stained granules than HFD-DR rats. Liver of
HFD-DR-Ex-MLD rats (Fig. 6e) showed almost a normal
liver architecture.
BP, blood glucose and insulin
Before experimental period there was no difference on
BP in each group (data not show). After the intervention
period, compared with the Cont rats, The HFD rats
showed a significant increase in BP (P < 0.01). Compared
with the HFD rats, HFD-DR, HFD-DR-Ex and HFD-DR-
Ex-MLD induced a significant decrease in BP (P < 0.01,
Fig. 7a). Before and after the intervention, the blood glu-
cose was measured by the fast blood glucose meter.
Compared with the Cont rats, the blood glucose levels
of HFD rats were significantly higher (P < 0.01, Fig. 7b);
compared with the HFD rats, the blood glucose levels of
HFD-DR, HFD-DR-Ex and HFD-DR-Ex-MLD were sig-
nificantly lower (P < 0.05 or 0.01). The level of insulin in
serum is demonstrated in Fig. 7c. Compared with Cont
rats, HFD group rats resulted in significant increase in
insulin in serum (P < 0.01). Compared with HFD rats,
levels of insulin in serum of HFD-DR-Ex and HFD-DR-
Ex-MLD resulted in significant decrease (P < 0.01).
The level of TNF-α, leptin and PKB in serum and liver
The level of TNF-α in serum and liver is demonstrated
in Fig. 8a. Compared with Cont rats, HFD rats resulted
in significant increase in TNF-α in serum and liver (P <
0.01). Compared with HFD rats, levels of TNF-α in
serum and liver of HFD-DR, HFD-DR-Ex and HFD-DR-
C
A B
Fig. 4 Changes in each group (n = 10) on AST (a), ALT (b) and ALP (c). Compared with Control group rats, ##P < 0.01; compared with HFD
rats, *P < 0.05, **P < 0.01, respectively
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Ex-MLD resulted in significant decrease (P < 0.05 or
0.01). The level of leptin in serum and liver is demon-
strated in Fig. 8b. Compared with Cont rats, HFD rats
resulted in significant increase in leptin in serum and
liver (P < 0.01). Compared with HFD rats, levels of leptin
in serum and liver of HFD-DR, HFD-DR-Ex and HFD-
DR-Ex-MLD resulted in significant decrease (P < 0.01).
The level of PKB in serum and liver is demonstrated in
Fig. 8c. Compared with Cont rats, HFD rats resulted in
significant increase in PKB in serum and liver (P < 0.01).
Compared with HFD rats, levels of PKB in serum and
liver for HFD-DR, HFD-DR-Ex and HFD-DR-Ex-MLD
rats significant decreased (P < 0.05 or 0.01) except serum
PKB level of HFD-DR rats.
Discussion
In past decades, studies have showed that the HFD pro-
motes development of obesity and that there is a direct
connection between dietary fat and the process of obes-
ity. HFD has turned out to be the main factor of obesity
[22]. The relationship between obesity and MS are also
well demonstrated in the documents, rapidly increased
body weight is also considered to be connected with MS
[23–25]. There also have evidences mentioned that HFD
can cause abnormal levels of leptin, insulin and PKB. In
our experiment, we fed HFD to induce obesity model
rats. The obesity models we made are in agreement with
a series of clinical syndrome of MS, including hyperten-
sion, hyperglycemia, hyperlipaemia, hyperinsulinism and
increased ratio of liver and tissue to body weight.
Our results showed that dietary restriction incorpo-
rated with aerobic exercise and MLD exhibited effects in
alleviating HFD-induced obesity and dyslipidemia. Obes-
ity plays a central role in MS, as shown in Fig. 2, HFD
caused a significant increase in body weight and adipose
tissue and liver mass in HFD group. These were
Fig. 5 Photomicrograph of rats liver in Cont rats (a), HFD rats (b), HFD-DR rats (c), HFD-DR-Ex rats (d) and HFD-DR-Ex-MLD rats (e). (HE × 200)
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significantly diminished by treatment, demonstrating an
anti-obesity effect of dietary restriction incorporated
with aerobic exercise and MLD. Moreover, compared
with that of HFD rats, the serum lipid profile was nor-
malized by treatment as serum TC, TG, LDL and FFA
levels were significantly decreased and the HDL levels
were significantly elevated. These findings are in agree-
ment with our previous work showing hypolipidemic ef-
fects of dietary restriction incorporated with MLD
treatment in patients [18, 19], which is largely due to in-
creased fecal lipid excretion.
Consumption of diets rich in fats can lead to hepatic
fat accumulation and liver dysfunctions [26], conditions
that are underlined by leakage of cellular enzymes, such
as AST, ALT and ALP [27]. In the present study, the ac-
tivity of these enzymes in serum from the HFD group of
rats were higher than those in the control group, which
indicates that the HFD group rats had severe liver cell
damage. After intervention, the activities of AST, ALT
and ALP in HFD-DR-Ex-MLD group decreased signifi-
cantly, demonstrating an attenuation effect on hepatic
necrosis. Combining the macroscopic observation and
histopathological observation of liver, we found that
compared to the model control group, dietary restric-
tion, dietary restriction incorporated with swimming ex-
ercise and dietary restriction incorporated with
swimming exercise and MLD can reduce fatty deposition
and decrease the degeneration in liver cells, liver of
HFD-DR-Ex-MLD rats showed almost a normal liver
architecture.
The endothelial dysfunction and increased BP play an
important role in the development of secondary cardio-
vascular complications in MS [28]. Dietary restriction
incorporated with exercise and MLD decreased signifi-
cantly hypertension. The results indicate that interven-
tion is very effective to prevent systolic BP increase. To
Fig. 6 PAS stain of rats liver in Cont rats (a), HFD rats (b), HFD-DR rats (c), HFD-DR-Ex rats (d) and HFD-DR-Ex-MLD rats (e). (PAS × 200)
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our knowledge, this is the first detailed description of
the hypotensive effect of MLD in HFD rats. Treatment
with dietary restriction incorporated with exercise and
MLD also improved parameters of type 2 diabetes. As
such, glucose levels were significantly lowered by treat-
ment. Moreover, the treatment can improve level of in-
sulin in serum. Insulin has significant relationship with
distribution of body fat. With the increase of adipose in
cell population, the sensitivity of the population de-
grades gradually decreased, which is an abnormal cell
axis feedback mechanism to produce hyperinsulinemia,
however, hyperinsulinemia can further aggravate the
blood lipid metabolic disorder. In our experiment, insu-
lin serum content of the HFD group rats greatly in-
creased. After intervention, serum insulin content in
HFD-DR-Ex and HFD-DR-Ex-MLD groups decreased
significantly.
To further investigate possible mechanisms of effect,
some relevant cytokine, hormone and enzyme such as
TNF-α, leptin and PKB were assayed simultaneously.
TNF-α is always associated with obesity and other
markers of inflammation [29]. Moreover, evidence
turned out those levels of TNF-α in liver and serum
from patients with MS who has the typical syndrome
found a similar association between TNF-α and insulin
resistance [30–32]. Our study demonstrates that after
intervention, the serum and liver TNF-α content are
significantly less in HFD-DR group, HFD-DR-Ex group
and HFD-DR-Ex-MLD group rats than HFD group rats.
Leptin is a hormone produced by adipocytes, leptin al-
ways control our food intake, energy metabolism, and
associated with sugar and fat metabolism, decrease the
level of TG, and promoted the sensitivity of liver and tis-
sue to insulin. Leptin can improve fatty liver independ-
ently of insulin sensitization and suppression of food
intake [33]. In our study, serum and liver leptin levels of
the HFD group rats increased significantly. After inter-
vention, serum and liver leptin levels in HFD-DR, HFD-
DR-Ex and HFD-DR-Ex-MLD group rats decreased sig-
nificantly. PKB, also known as Akt, is a serine/threo-
nine-specific protein kinase that plays a key role in
multiple cellular processes such as glucose metabolism,
apoptosis, cell proliferation, transcription and cell mi-
gration; MS fails to activate PKB in cells [34, 35]. Im-
paired activation of PKB not only inhibits the metabolic
functions of insulin, including its ability to induce
glucose transport and glycogen synthesis, but it also
impairs the growth-promoting and antiapoptotic func-
tions of insulin and its related ligand the insulin-like
growth factor-1 [36]. Our study demonstrates that diet-
ary restriction incorporated with exercise or MLD sig-
nificantly decreases PKB in serum and liver. These
results indicated that the underlying mechanisms of




Fig. 7 Changes of BP (a), blood glucose (b) and insulin (c) in each group (n = 10). Compared with Control group rats, ##P < 0.01; compared with
HFD rats, *P < 0.05, **P < 0.01, respectively
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are relevant with secretion or activation of TNF-α, leptin
and PKB in serum and liver.
Conclusions
In summary, MLD incorporated with dietary restriction
and exercise treatment exhibit effects in alleviating
high-fat diet-induced obesity, hyperglycemia, hyperlip-
idemia, hypertension, hepatic injury and insulin resist-
ance, which are possibly due to the down-regulation
of TNF-α, leptin and PKB; and this treatment can be
used as a new therapeutic schedule of high-fat diet-
induced MS.
Fig. 8 Changes of TNF-α (a), leptin (b) and PKB (c) in serum and liver (n = 10). Compared with Control group rats, ##P < 0.01; compared with HFD
rats, *P < 0.05, **P < 0.01, respectively
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